Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexidol in primary open-angle glaucoma
NCT06437639Phase 4Completed
- Sponsor
- Pharmasoft
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of emoxypine in primary open-angle glaucoma (POAG), sponsored by Pharmasoft. Started Sep 2023; status: completed.
02
Drugs
emoxypine
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT06437639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437639.